# Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease

> **NCT04727528** · PHASE3 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 39 (actual)

## Conditions studied

- Hyperkalaemia
- Metabolic Acidosis
- Chronic Kidney Disease

## Interventions

- **DRUG:** Sodium zirconium cyclosilicate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04727528
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-22
- **Primary completion:** 2022-09-14
- **Final completion:** 2022-09-14
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** The study was stopped due to a higher than expected screen fail rate (83%) which lead to very low patient enrollment into the study. It should be noted that the decision to terminate the study is not related to safety concerns.
- **Last updated:** 2023-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04727528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04727528, "Study of the Effect of SZC on Serum Potassium and Serum Bicarbonate in Patients With Hyperkalemia and Metabolic Acidosis Associated With Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04727528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*